Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quick Listen: Scrip's Five Must-Know Things

Executive Summary

In this week's podcast version of Five Must-Know Things: US prospects for Sarepta’s DMD gene therapy; looking at price increases in the US; Eisai plans US CMS coverage for lecanemab; vaccine impact as China rolls back COVID zero policies; and ex-Novo Nordisk CEO Mads Øvlisen shares his career and life lessons.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 9 December 2022, including: US prospects for Sarepta Therapeutics, Inc.’s DMD gene therapy; looking at price increases in the US; Eisai Co., Ltd. plans US CMS coverage for lecanemab; vaccine impact as China rolls back COVID zero policies; and ex-Novo Nordisk A/S CEO Mads Øvlisen shares his career and life lessons.

This and all our other podcasts are available on the Pharma Intelligence channel on Apple PodcastsGoogle PodcastsSoundCloudTuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.  

Stories mentioned in this episode:

(Also see "A Duchenne Breakthrough Awaits In 2023 - But Risks Remain For Sarepta And US FDA" - Scrip, 6 Dec, 2022.)

(Also see "Drugs From Bausch, J&J And Amgen Top ICER's Unsupported Price Increase List" - Scrip, 6 Dec, 2022.)

(Also see "Eisai Plots A Meticulous Path To CMS Coverage For Lecanemab" - Scrip, 2 Dec, 2022.)

(Also see "China Winds Down 'COVID Zero' But Vaccine Fatigue, Other Worries Linger" - Scrip, 6 Dec, 2022.)

(Also see "Lessons From Novo Nordisk’s Mads Øvlisen, The Father Of CSR" - Scrip, 6 Dec, 2022.)

 

 
 

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel